COVID-19
Lifting the clinical hold will allow Ocugen to continue to assess the vaccine in its ongoing study and potentially support its efforts to achieve EUA or full approval.
A small research study published in Jama shows people with a lower body mass index (BMI) tended to maintain immunity against COVID-19 longer.
Vir Biotechnology terminated a two-year-old COVID-19-related antibody collaboration with Wuxi Biologics that included sotrovimab, which lost EUA in the U.S. earlier this year.
Based on topline data, Pfizer stated that three doses of the COVID-19 vaccine met all immunobridging criteria required for EUA. The FDA’s advisory committee will meet June 15 to discuss the matter.
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
Following reports that Pfizer has declined study requests for Paxlovid, the company and NIH are said to be in conversation about potential studies assessing a longer treatment period of the antiviral.
Pfizer apparently hasn’t begun any combination trials in human beings of Paxlovid, and no reported human tests are using the drug in combination with other therapies.
Scientists in New Zealand have found that mRNA-based COVID-19 vaccines produce greater antibody levels compared to adenovirus vector-based ones across major COVID-19 variants.
Moderna held its first in-person Science and Technology Day since 2019. Notably, the company shared information about its new inhalable lipid nanoparticles (LNPs).
RQ Biotechnology has officially launched, with the financial backing of AstraZeneca. The move strategically increases the availability of monoclonal antibodies at a time of ever-increasing demand.
PRESS RELEASES